Skip to main content
Delayed
Smart Investors Daily
AD

NASDAQ · ADCT

ADC Therapeutics S.A.

Healthcare · Biotechnology

$1.23

Down-$0.03 (-2.38%)

Updated Sep 30, 2026, 5:03 AM

SID Score

4.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
507.9M
P/E ratio
-3.35
Dividend yield
0.00%
52-week range
$0.78 – $4.98
Volume
781.02K
Avg. volume
1.16M

Price performance · ADCT

ADCT price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Sep 29, 2026

ADCT closed at $1.23 after 20 trading sessions, down 0.81% for the selected period.

Last close
$1.23
Period change
-0.81%
Period low
$1.05
Period high
$1.36
Daily close
View OHLC price history
ADCT OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 29, 2026$1.27$1.29$1.20$1.23781.02K
Sep 28, 2026$1.24$1.27$1.20$1.26835.12K
Sep 25, 2026$1.26$1.285$1.21$1.271.08M
Sep 24, 2026$1.305$1.31$1.24$1.291.58M
Sep 23, 2026$1.24$1.32$1.21$1.311.97M
Sep 22, 2026$1.13$1.25$1.12$1.231.67M
Sep 21, 2026$1.05$1.13$1.035$1.121.9M
Sep 18, 2026$1.06$1.145$1.05$1.051.58M
Sep 17, 2026$1.06$1.10$1.01$1.061.55M
Sep 16, 2026$1.09$1.095$1.025$1.053.32M
Sep 15, 2026$1.12$1.12$1.03$1.091.26M
Sep 14, 2026$1.07$1.12$1.06$1.11808.48K
Sep 11, 2026$1.13$1.156$1.04$1.07989.11K
Sep 10, 2026$1.21$1.24$1.07$1.11957.19K
Sep 9, 2026$1.28$1.31$1.191$1.221.71M
Sep 8, 2026$1.33$1.35$1.27$1.30930.76K
Sep 4, 2026$1.30$1.37$1.30$1.361.48M
Sep 3, 2026$1.32$1.37$1.30$1.322.77M
Sep 2, 2026$1.23$1.35$1.23$1.321.96M
Sep 1, 2026$1.15$1.24$1.14$1.241.15M

Latest ADCT news

The latest Smart Investors Daily articles mentioning ADCT.

Stock researchCompany · Overview

Company

OverviewForecastEarnings — requires Earnings Calls and Results accessDividend — requires Dividend Research accessFinancials

Market Activity

OptionsInsider Trades — requires Insider Buying and Selling accessShort InterestInstitutional Ownership — requires Institutional Ownership accessSentiment

ADCT research

Overview

Company profile and research snapshot.

Company profile

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$7.50
Implied upside
—
Analysts
—
ADCT recent ratings
DateFirmRatingTarget
Aug 17, 2026GuggenheimBuy—
Jun 8, 2026HC Wainwright & Co.Neutral—
Jun 4, 2026RBC CapitalSector Perform—
May 5, 2026RBC CapitalOutperform—
May 5, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 27, 2026

ADC Therapeutics (ADCT) Navigates FDA Setback While Cutting Its Losses

On August 13, ADC Therapeutics (NYSE:ADCT) held its second-quarter earnings call and delivered a mixed message that investors are still sorting through. The company’s confirmatory trial for ZYNLONTA in second-line lymphoma cleared its main efficacy bar, but the FDA has flagged serious safety concerns about the combination that could complicate its path to a fuller […]

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.